Pfizer and Valneva Phase 3 Lyme Disease Vaccine Trial Shows Over 70 Per Cent Efficacy

Key facts

• Pfizer and the French pharmaceutical company Valneva reported an efficacy of at least 73 per cent in Phase 3 of a randomised clinical vaccine trial for Lyme disease.
• The clinical trial involved 9,400 participants aged 5 and older to evaluate the safety and effectiveness of the vaccine.
• Medical experts from Stony Brook University Hospital and NYU Langone Long Island noted the vaccine could prevent severe complications such as Lyme meningitis and Lyme arthritis.
• According to the New York State Department of Health (NYSDOH), Suffolk County recorded over 3,000 cases of Lyme disease in 2024, the highest in the state, while Nassau County recorded 521 cases.
• The pharmaceutical companies intend to seek federal approval for the vaccine as there is currently no Lyme vaccine available for humans.